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Julie Earl1,2, Daniel Rico3, Enrique Carrillo-de-Santa-Pau1, Benjamín Rodríguez-Santiago4,6, Marinela Méndez-Pertuz1,
Herbert Auer7, Gonzalo Gómez8, H. Barton Grossman9, David G. Pisano8, Wolfgang A. Schulz10,
Luis A. Pérez-Jurado5,6, Alfredo Carrato2, Dan Theodorescu11, Stephen Chanock12, Alfonso Valencia3
and Francisco X. Real1,5*Keywords: Urothelial bladder cancer, Cell line, Genomics, Mutation, Oncogene, Tumor suppressorFollowing the publication of our recent article in BMC
Genomics [1] a number of aspects were called to our at-
tention. We have carefully reviewed the experiments re-
ported in this manuscript, as well as additional data
from our laboratories, and would like to make the fol-
lowing points:
1. SW-850, included in our paper as a bladder cancer
cell line, has been reported by several authors to be
a pancreatic cancer cell line [2–5]. This is unlikely
to be the case given that most pancreatic cancers
are KRAS-mutant and both our analysis and a previous
publication [5] indicate that the cells used are KRAS-
wild type. However, given the controversy we
recommend that these cells are not be used as
bladder cancer models.
2. The Materials and Methods section of our paper
indicated that the following cell lines were obtained
from ATCC: 253 J, 575A, 639 V, JON, MGH-U4, SW-
800, SW-1710, VM-CUB-2. However, these cultures
have never been distributed by the ATCC. Therefore,
they are available from us if other investigators are
interested in using them.
3. It has been reported that UM-UC-2 is a T24 con-
taminant (http://www.ncbi.nlm.nih.gov/biosample/* Correspondence: preal@cnio.es
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fingerprinting analysis to confirm this fact and the
genetic identity of the cells/DNAs used in our ex-
periments (Table 1).




losaurus/CVCL_9830). Nevertheless, our data indicate
that the two cultures we used as VM-CUB-1 and VM-
CUB-3 are distinct at the genomic level. Furthermore,
as shown in Table 1, fingerprinting analysis clearly indi-
cates that VM-CUB-1, VM-CUB-2, and VM-CUB-3
are different from each other. The origin of the DNA/
cells in our paper was as indicated in the Material and
Methods section and, therefore, investigators interested
in these cells could directly address the corresponding
co-authors.
In the last few years there has been much emphasis
on the need to accurately designate, identify, and
characterize cancer cell lines as they are precious tools
for cell biology studies [6, 7]. It is with this aim that we
wish to make these comments and clarifications related
to our recently published work.distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 SNP fingerprint analysis of the bladder cancer cell lines suffering from an “identity crisis”
Cell Line Comments D5S818 D13S317 D7S820 D16S539 VWA TH01 AM TPOX CSF1PO
VM- CUB-1 p29 11 10 8,11 11,12 18,19 9 X 8 11
VM-CUB-2 p112 11,13 12 8 9 14 7 X,Y 8,12 11,12
VM-CUB-3 p65 11 9,12 8,9 12 16 9.3 X 8 12
UM-UC-2 p264 DNA fingerprinting
data, same as T24
10,12 10,12 10,11 9 17 6 X 8,11 10,12
T24 p8 ATCC 10,12 12 10,11 9 17,19 6 X 8,11 10,12
P passage
Earl et al. BMC Genomics  (2015) 16:1019 Page 2 of 2Competing interests
The authors declare no competing financial interests.
Author details
1Epithelial Carcinogenesis Group, F BBVA Cancer Cell Biology Programme,
CNIO (Spanish National Cancer Research Centre), Melchor Fernández
Almagro, 3, 28029 Madrid, Spain. 2Servicio de Oncología Médica, Hospital
Ramón y Cajal, Madrid, Spain. 3Structural Computational Biology Group,
Structural Biology and Biocomputing Programme, CNIO (Spanish National
Cancer Research Centre), Madrid, Spain. 4Quantitative Genomic Medicine
Laboratory, qGenomics, Barcelona, Spain. 5Departament de Ciències
Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.
6Centro de Investigación Biomédica en Red de Enfermedades Raras
(CIBERER), Barcelona, Spain. 7Institut de Recerca Biomèdica de Barcelona, Parc
Científic de Barcelona, Barcelona, Spain. 8Bioinformatics Unit, Structural
Biology and Biocomputing Programme, CNIO (Spanish National Cancer
Research Centre), Madrid, Spain. 9Department of Urology, MD Anderson
Cancer Center, Houston, TX, USA. 10Department of Urology,
Heinrich-Heine-University, Düsseldorf, Germany. 11University of Colorado
Comprehensive Cancer Center, Aurora, CO 80045, USA. 12Translational
Genomics Laboratory, Division of Cancer Epidemiology and Genetics,
National Cancer Institute, Bethesda, USA.
Received: 18 November 2015 Accepted: 18 November 2015
References
1. Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodríguez-Santiago B, Méndez M,
Auer H, et al. The UBC-40 Urothelial Bladder Cancer Cell Line Index: a
genomic resource for functional studies. BMC Genomics. 2015;16:403.
2. Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human
tumor cell lines producing tumors in nude mice. J Natl Cancer Inst. 1977;
59(1):221–6.
3. Fogh J, Wright WC, Loveless JD. Absence of HeLa cell contamination in 169
cell lines derived from human tumors. J Natl Cancer Inst. 1977;58(2):209–14.
4. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, et al. p53
and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene. 1993;
8(2):289–98.
5. Müller C, Bockhorn AG, Klusmeier S, Kiehl M, Roeder C, Kalthoff H, et al.
Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as
well as with wild-type K-ras oncogene but has different effects on protein
phosphorylation and induction of apoptosis. Int J Oncol. 1998;12(3):717–23.
6. Freedman LP, Gibson MC, Ethier SP, Soule HR, Neve RM, Reid YA.
Reproducibility: changing the policies and culture of cell line authentication.
Nat Methods. 2015;12(6):493–7.
7. Yu M, Selvaraj SK, Liang-Chu MM, Aghajani S, Busse M, Yuan J, et al. A
resource for cell line authentication, annotation and quality control. Nature.
2015;520(7547):307–11.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
